Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Intuitive Surgical Inc. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Income Statement
- Analysis of Short-term (Operating) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Dividend Discount Model (DDM)
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Intuitive Surgical Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
Profitability metrics exhibit a cyclical pattern characterized by a period of contraction between early 2022 and early 2023, followed by a consistent recovery phase extending through March 2026. While top-line efficiency faced a gradual decline, operational and bottom-line margins, alongside capital efficiency ratios, demonstrated significant expansion in the latter half of the period.
- Gross Profit Margin
- A gradual downward trend is observed in the gross profit margin, which declined from 68.84% in March 2022 to a low of 66.39% by December 2023. Despite minor fluctuations and a slight recovery in late 2024, the margin stabilized at 66.29% by March 2026. This suggests a long-term, slight increase in the cost of sales relative to total revenue.
- Operating and Net Profit Margins
- Operational profitability underwent a U-shaped trajectory. The operating profit margin contracted from 30.69% in March 2022 to a trough of 24.21% in March 2023, before initiating a steady climb to reach 30.45% by March 2026. Net profit margins mirrored this movement, dropping from 27.84% to 20.40% in the same initial period, then recovering to stabilize between 28.15% and 28.58% from 2024 through early 2026. This indicates a successful optimization of operating expenses and an improvement in overall bottom-line efficiency.
- Return on Equity (ROE) and Return on Assets (ROA)
- Efficiency ratios show a strong positive trend following the 2023 lows. Return on Equity declined initially to 11.70% in March 2023 but subsequently grew consistently to reach 17.05% by March 2026. Similarly, Return on Assets moved from a low of 10.05% in March 2023 to 14.81% by March 2026. The simultaneous rise in both ROE and ROA suggests improved asset utilization and enhanced shareholder value generation over the analyzed timeframe.
Return on Sales
Return on Investment
Gross Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Gross profit margin = 100
× (Gross profitQ1 2026
+ Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
Analysis of the financial performance indicates a sustained increase in both total revenue and gross profit over the period from March 31, 2022, to March 31, 2026. Despite the growth in absolute figures, the gross profit margin has experienced a general contraction, characterized by an initial decline, a mid-period recovery, and a subsequent softening.
- Revenue and Gross Profit Trajectory
- Revenue increased from 1.487 billion USD in March 2022 to 2.770 billion USD by March 2026. Simultaneously, gross profit grew from 1.009 billion USD to 1.830 billion USD. This demonstrates a consistent capacity for top-line expansion and a significant increase in the total profit generated before operating expenses.
- Gross Profit Margin Trends
- The gross profit margin began at 68.84% in March 2022 and followed a consistent downward trajectory for nearly two years, reaching a low of 66.39% in December 2023. This suggests that the cost of goods sold grew at a faster rate than revenue during this initial phase.
- Margin Recovery and Subsequent Volatility
- A period of recovery occurred between March 2024 and December 2024, during which the margin climbed to a peak of 67.46%. However, this recovery was not sustained, as the margin declined again to 66.00% by December 2025, before ending the analyzed period at 66.29% in March 2026.
- Overall Profitability Efficiency
- While the organization successfully scaled its operations, the overall efficiency of production or service delivery, as measured by the gross profit margin, decreased by approximately 2.55 percentage points over the analyzed timeframe. The fluctuations observed indicate a dynamic cost environment or potential shifts in the product mix.
Operating Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Income from operations | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Operating profit margin = 100
× (Income from operationsQ1 2026
+ Income from operationsQ4 2025
+ Income from operationsQ3 2025
+ Income from operationsQ2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The operating profit margin exhibits a U-shaped trajectory over the analyzed period, characterized by an initial contraction followed by a sustained recovery. While revenue grew consistently from US$ 1,487,700 thousand in March 2022 to US$ 2,770,800 thousand by March 2026, the profitability ratio fluctuated, ultimately returning to near-initial levels.
- Margin Contraction Phase
- Between March 2022 and March 2023, a notable downward trend in the operating profit margin is observed, falling from 30.69% to a period low of 24.21%. During this window, revenue increased by approximately 13.7%, yet income from operations declined from US$ 408,100 thousand to US$ 387,600 thousand, suggesting that operating expenses grew at a disproportionate rate relative to revenue gains.
- Stabilization and Recovery Phase
- From June 2023 through December 2024, the operating profit margin began a steady ascent, recovering from 24.34% to 28.12%. This phase is marked by an acceleration in operational efficiency, as income from operations rose significantly from US$ 463,200 thousand to US$ 734,900 thousand. This indicates a successful realignment of cost structures as the company scaled its revenue to over US$ 2.4 billion.
- Profitability Normalization and Scaling
- The period from March 2025 to March 2026 shows a continuation of margin expansion, culminating in a profit margin of 30.45%. The synchronization of aggressive revenue growth—reaching a peak of US$ 2,866,200 thousand in December 2025—with a corresponding rise in operating income to US$ 864,300 thousand demonstrates strong operating leverage. The recovery to the 30% threshold suggests a return to the company's baseline operational efficiency despite a significantly larger revenue base.
Net Profit Margin
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | |||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
Net profit margin = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2026
+ Net income attributable to Intuitive Surgical, Inc.Q4 2025
+ Net income attributable to Intuitive Surgical, Inc.Q3 2025
+ Net income attributable to Intuitive Surgical, Inc.Q2 2025)
÷ (RevenueQ1 2026
+ RevenueQ4 2025
+ RevenueQ3 2025
+ RevenueQ2 2025)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
An analysis of the net profit margin reveals a distinct U-shaped trajectory over the period from March 2022 to March 2026. After an initial period of contraction, the profitability ratio experienced a robust recovery and subsequently entered a phase of stabilization at a higher baseline.
- Margin Contraction (March 2022 – March 2023)
- A consistent decline in profitability is observed during the first year of the period. The net profit margin fell from 27.84% in March 2022 to a trough of 20.40% in March 2023, representing a contraction of 7.44 percentage points.
- Profitability Recovery (March 2023 – September 2024)
- Following the March 2023 low, a systematic recovery occurred. The margin increased steadily throughout 2023 and 2024, regaining its pre-contraction levels by the first quarter of 2024 and reaching a peak of 28.51% by September 2024.
- Operational Stabilization (September 2024 – March 2026)
- The final eighteen months of the analyzed period demonstrate high stability. The net profit margin fluctuated minimally, remaining within a tight corridor between 27.81% and 28.58%, which suggests a sustainable equilibrium in cost management relative to revenue growth.
The expansion of the net profit margin coincided with a significant increase in total revenue, which grew from 1.49 billion in March 2022 to 2.77 billion by March 2026. The fact that net income grew more rapidly than revenue during the recovery phase indicates an improvement in operational leverage and overall efficiency.
Return on Equity (ROE)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | |||||||||||||||||||||||
| Total Intuitive Surgical, Inc. stockholders’ equity | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROE = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2026
+ Net income attributable to Intuitive Surgical, Inc.Q4 2025
+ Net income attributable to Intuitive Surgical, Inc.Q3 2025
+ Net income attributable to Intuitive Surgical, Inc.Q2 2025)
÷ Total Intuitive Surgical, Inc. stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance over the analyzed period demonstrates a sustained improvement in profitability and capital efficiency, characterized by an accelerating growth in net income relative to stockholders' equity.
- Net Income Trajectory
- A period of relative stability with slight fluctuations was observed throughout 2022, with quarterly net income ranging between 307.8 million and 365.6 million US dollars. A consistent upward trend emerged starting in 2023, marked by a significant increase to 606.2 million US dollars by December 31, 2023. This growth trajectory continued through 2024 and 2025, culminating in a peak of 821.5 million US dollars by March 31, 2026.
- Stockholders' Equity Evolution
- Total stockholders' equity experienced a moderate decline during 2022, decreasing from 12.1 billion to 11.0 billion US dollars. Following this contraction, equity grew steadily and linearly from March 2023 through March 2026, reaching 17.47 billion US dollars. This indicates a consistent accumulation of capital or retained earnings over the latter three years of the period.
- Return on Equity (ROE) Analysis
- The ROE exhibited a U-shaped recovery pattern. Initial levels of 13.58% in March 2022 declined to a low of 11.70% by March 2023. A recovery phase began in late 2023, with the ratio returning to 13.51% by December 31, 2023. From 2024 onwards, ROE entered a phase of expansion, consistently exceeding 14% and reaching a period high of 17.05% by March 31, 2026. This expansion indicates that net income growth significantly outpaced the growth of the equity base in the final eight quarters of the analysis.
Return on Assets (ROA)
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||
| Net income attributable to Intuitive Surgical, Inc. | |||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||
| Abbott Laboratories | |||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||
Based on: 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q1 2026 Calculation
ROA = 100
× (Net income attributable to Intuitive Surgical, Inc.Q1 2026
+ Net income attributable to Intuitive Surgical, Inc.Q4 2025
+ Net income attributable to Intuitive Surgical, Inc.Q3 2025
+ Net income attributable to Intuitive Surgical, Inc.Q2 2025)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial performance over the observed period demonstrates a significant upward trajectory in profitability and asset utilization efficiency. While the initial phase showed a slight contraction in the return on assets, the subsequent periods reflect a robust recovery and sustained growth in net income that has outpaced the expansion of the asset base.
- Net Income Growth
- Net income exhibits a strong long-term growth trend, increasing from 365,600 thousand US dollars in March 2022 to 821,500 thousand US dollars by March 2026. A notable acceleration is observed starting in late 2023, with quarterly earnings consistently remaining above the 500,000 thousand US dollar threshold from March 2024 onward, indicating a substantial increase in bottom-line profitability.
- Total Asset Expansion
- The asset base expanded steadily from 13,678,400 thousand US dollars in March 2022 to 20,111,000 thousand US dollars in March 2026. Despite a brief period of contraction throughout 2022, the overall trend reflects a consistent investment in the balance sheet, with total assets growing by approximately 47% over the analyzed timeframe.
- Return on Assets (ROA) Analysis
- The ROA followed a U-shaped trajectory. An initial decline is observed from March 2022 (12.02%) to a low of 10.05% in March 2023. Following this trough, a period of steady recovery ensued, with the ratio climbing back above 12% by March 2024. The final phase of the analysis reveals a further acceleration in efficiency, peaking at 14.81% in March 2026. This indicates that the company has successfully optimized its asset utilization, generating higher returns for every dollar of assets employed.
The correlation between the accelerating net income and the rising ROA suggests that the company has achieved positive operating leverage. The growth in profitability is not merely a result of increasing the asset base, but rather an improvement in the fundamental efficiency of those assets in generating net earnings.